Background: One of the main immune escape mechanisms used by tumors is the exploitation of immune
checkpoints – receptors on surface of immune cells, which, after binding their ligands,
can suppress immune response. Consequently, immune checkpoint blockade is considered
as promising approach for cancer treatment. However, currently available anti-CTLA-4
and anti-PD-1/anti-PD-L1 drugs have shown limited efficiency against many common cancer
types (e.g. breast cancer). This research aims to identify in what way the shifts
in miRNA expression pattern can contribute to the resistance of breast cancer cells
to the immune checkpoint inhibitors and to the weakening of their efficiency during
treatment.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P03.02
Identification
Copyright
© 2018 Published by Elsevier Inc.
